We just don’t see many stories that profile someone who declines aggressive treatment for prostate cancer and chooses watchful waiting – or active surveillance – instead.
But that’s what Judith Graham of the Chicago Tribune delivered yesterday, explaining that:
“…for the first time it’s being endorsed for large numbers of men by a major medical organization: the National Comprehensive Cancer Network, an alliance of 21 leading cancer centers across the U.S.
In new guidelines, NCCN recommends active surveillance for men deemed to have “very low risk” prostate cancer and a life expectancy of less than 20 years. Also, the organization recommends the strategy if a man’s prostate cancer is considered “low risk” and his life expectancy is less than 10 years.”